| 品牌 | 其他品牌 | 货号 | BFN60800660 |
|---|---|---|---|
| 规格 | T25培养瓶x1 1.5ml冻存管x2 | 供货周期 | 现货 |
| 主要用途 | 仅供科研 | 应用领域 | 医疗卫生,生物产业 |
细胞名称 | 人肺鳞癌细胞SK-MES-1 |
| |
货物编码 | BFN60800660 | ||
产品规格 | T25培养瓶x1 | 1.5ml冻存管x2 | |
细胞数量 | 1x10^6 | 1x10^6 | |
保存温度 | 37℃ | -198℃ | |
运输方式 | 常温保温运输 | 干冰运输 | |
安全等级 | 1 | ||
用途限制 | 仅供科研用途 1类 | ||
培养体系 | DMEM高糖培养基（Hyclone）+10%胎牛血清（Gibco）+1%双抗（Hyclone） | ||
培养温度 | 37℃ | 二氧化碳浓度 | 5% |
简介 | 人肺鳞癌细胞SK-MES-1细胞源于一位65岁患有肺鳞状细胞癌的白人男性，自转移性胸腔积液分离而来。由青旗（上海）生物技术发展有限公司于2018年引种自ATCC（HTB-58)。 | ||
注释 | Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: MD Anderson Cell Lines Project. From: Memorial Sloan Kettering Cancer Center; New York; USA. Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2009-091. Doubling time: ~50 hours (DSMZ). Microsatellite instability: Stable (MSS) (Sanger). Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: SNP array analysis. Omics: Transcriptome analysis. | ||
STR信息 | Amelogenin：X，Y；CSF1PO：12；D13S317：11；D16S539：13；D18S51：17；D19S433：14；D21S11：29，30；D2S1338：19；D3S1358：16；D5S818：11；D7S820：8；D8S1179：13，14；FGA：20，24；TH01：6，9.3；TPOX：8；vWA：14； | ||
参考文献 | DOI=10.1007/978-1-4757-1647-4_5 Fogh J., Trempe G.L. New human tumor cell lines. (In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975)
PubMed=833871; DOI=10.1093/jnci/58.2.209 Fogh J., Wright W.C., Loveless J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58:209-214(1977)
PubMed=6935474; DOI=10.1093/jnci/66.2.239 Wright W.C., Daniels W.P., Fogh J. Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis. J. Natl. Cancer Inst. 66:239-247(1981)
PubMed=7017212; DOI=10.1093/jnci/66.6.1003 Pollack M.S., Heagney S.D., Livingston P.O., Fogh J. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66:1003-1012(1981)
PubMed=2990217 Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M. Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am. J. Pathol. 119:361-366(1985)
PubMed=4005855 Kyoizumi S., Akiyama M., Kouno N., Kobuke K., Hakoda M., Jones S.L., Yamakido M. Monoclonal antibodies to human squamous cell carcinoma of the lung and their application to tumor diagnosis. Cancer Res. 45:3274-3281(1985)
PubMed=3518877; DOI=10.3109/07357908609038260 Fogh J. Human tumor lines for cancer research. Cancer Invest. 4:157-184(1986)
PubMed=3335022 Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:589-601(1988)
PubMed=8385084; DOI=10.1111/j.1349-7006.1993.tb02851.x Suzuki S., Takahashi T., Nakamura S., Koike K., Ariyoshi Y., Takahashi T., Ueda R. Alterations of integrin expression in human lung cancer. Jpn. J. Cancer Res. 84:168-174(1993)
PubMed=7736387; DOI=10.1002/1097-0142(19950515)75:10<2442::AID-CNCR2820751009>3.0.CO;2-Q Campling B.G., Sarda I.R., Baer K.A., Pang S.C., Baker H.M., Lofters W.S., Flynn T.G. Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer. Cancer 75:2442-2451(1995)
PubMed=12794755; DOI=10.1002/ijc.11184 Endoh H., Yatabe Y., Shimizu S., Tajima K., Kuwano H., Takahashi T., Mitsudomi T. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int. J. Cancer 106:45-51(2003)
PubMed=14581340 Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J. TERC identified as a probable target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin. Cancer Res. 9:4705-4713(2003)
PubMed=15746151; DOI=10.1093/hmg/ddi092 Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M., Hirohashi S., Inazawa J., Imoto I. Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in non-small cell lung cancers. Hum. Mol. Genet. 14:997-1007(2005)
PubMed=18083107; DOI=10.1016/j.cell.2007.11.025 Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203(2007)
PubMed=19472407; DOI=10.1002/humu.21028 Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M. A gene-alteration profile of human lung cancer cell lines. Hum. Mutat. 30:1199-1206(2009)
PubMed=20164919; DOI=10.1038/nature08768 Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458 Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70:2158-2164(2010)
PubMed=22460905; DOI=10.1038/nature11003 Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607(2012)
PubMed=24002593; DOI=10.1038/bjc.2013.452 Wu D., Pang Y., Wilkerson M.D., Wang D., Hammerman P.S., Liu J.S. Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity. Br. J. Cancer 109:1599-1608(2013)
PubMed=25485619; DOI=10.1038/nbt.3080 Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33:306-312(2015)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016)
PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) | ||
验收细胞注意事项
1、收到人肺鳞癌细胞SK-MES-1，请查看瓶子是否有破裂，培养基是否漏出，是否浑浊，如有请尽快联系。
2、收到人肺鳞癌细胞SK-MES-1 ，如包装完好，请在显微镜下观察细胞。,由于运输过程中的问题，细胞培养瓶中的贴壁细胞有可能从瓶壁中脱落下来，显微镜下观察会出现细胞悬浮的情况，出现此状态时，请不要打开细胞培养瓶，应立即将培养瓶置于细胞培养箱里静止 3-5 小时左右，让细胞先稳定下，再于显微镜下观察，此时多数细胞会重新贴附于瓶壁。如细胞仍不能贴壁，请用台盼蓝染色法鉴定细胞活力，如台盼蓝染色证实细胞活力正常请按悬浮细胞的方法处理。
3、收到人肺鳞癌细胞SK-MES-1后，请镜下观察细胞，用恰当方式处理细胞。若悬浮的细胞较多，请离心收集细胞，接种到一个新的培养瓶中。弃掉原液，使用新鲜配制的培养基，使用进口胎牛血清。刚接到细胞，若细胞不多时 血清浓度可以加到 15％去培养。若细胞迏到 80%左右 ，血清浓度还是在 10％。
4、收到人肺鳞癌细胞SK-MES-1时如无异常情况 ，请在显微镜下观察细胞密度，如为贴壁细胞，未超过80%汇合度时，将培养瓶中培养基吸出，留下 5-10ML 培养基继续培养：超过 80%汇合度时，请按细胞培养条件传代培养。如为悬浮细胞，吸出培养液，1000 转/分钟离心 3 分钟，吸出上清，管底细胞用新鲜培养基悬浮细胞后移回培养瓶。
5、将培养瓶置于 37℃培养箱中培养，盖子微微拧松。吸出的培养基可以保存在灭菌过的瓶子里，存放于 4℃冰箱，以备不时之需。
6、24 小时后，细胞形态已恢复并贴满瓶壁，即可传代。（贴壁细胞）将培养瓶里的培养基倒去，加 3-5ml（以能覆盖细胞生长面为准）PBS 或 Hanks’液洗涤后弃去。加 0.5-1ml 0.25%含 EDTA 的胰酶消化，消化时间以具体细胞为准，一般 1-3 分钟，不超过 5 分钟。可以放入37℃培养箱消化。轻轻晃动瓶壁，见细胞脱落下来，加入 3-5ml 培养基终止消化。用移液管轻轻吹打瓶壁上的细胞，使之*脱落，然后将溶液吸入离心管内离心，1000rpm/5min。弃上清，视细胞数量决定分瓶数，一般一传二，如细胞量多可一传三，有些细胞不易传得过稀，有些生长较快的细胞则可以多传几瓶，以具体细胞和经验为准。（悬浮细胞）用移液管轻轻吹打瓶壁，直接将溶液吸入离心管离心即可。
7、贴壁细胞 ，悬浮细胞。严格无菌操作。换液时，换新的细胞培养瓶和换新鲜的培养液，37℃，5%CO2 培养。
特别提醒： 原瓶中培养基不宜继续使用，请更换新鲜培养基培养。
青旗（上海）生物技术发展有限公司，总部位于上海浦东新区，依托本地高校资源，逐步发展成为以生物技术为主的研发、生产、培训为一体的综合化产业平台，在标准化细胞库建立及细胞药物前端模型方面成果显著。公司生产经营原代细胞、细胞系、ELISA试剂盒、感受态细胞和HPLC检测等科研产品与服务。我们秉承对用户负责的态度，以对科研的高度严谨，以严格的质量控制，为广大生物医学科研用户提供更优质的服务！
您的位置：
地址：上海市浦东新区宏祥北路83号
邮箱：cellsupport@bluefcell.com
传真：
咨询电话